Abeona Therapeutics Inc. (NASDAQ:ABEO) posted its earnings results on Tuesday. The biopharmaceutical company reported ($0.21) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.14) by $0.07, Bloomberg Earnings reports. The firm had revenue of $0.22 million for the quarter, compared to analysts’ expectations of $0.21 million. Abeona Therapeutics had a negative return on equity of 26.99% and a negative net margin of 2,568.57%.

Abeona Therapeutics (ABEO) traded up 1.23% during trading on Wednesday, hitting $8.20. 78,473 shares of the stock traded hands. Abeona Therapeutics has a 12 month low of $3.90 and a 12 month high of $10.26. The firm’s market cap is $330.09 million. The firm has a 50-day moving average price of $8.18 and a 200 day moving average price of $6.02.

An institutional investor recently bought a new position in Abeona Therapeutics stock. California State Teachers Retirement System purchased a new stake in Abeona Therapeutics Inc. (NASDAQ:ABEO) during the second quarter, according to its most recent filing with the SEC. The fund purchased 42,900 shares of the biopharmaceutical company’s stock, valued at approximately $275,000. California State Teachers Retirement System owned about 0.11% of Abeona Therapeutics as of its most recent SEC filing. Hedge funds and other institutional investors own 36.15% of the company’s stock.

WARNING: This article was originally reported by American Banking News and is the property of of American Banking News. If you are viewing this article on another site, it was copied illegally and republished in violation of United States & international copyright and trademark laws. The legal version of this article can be read at https://www.americanbankingnews.com/2017/08/16/abeona-therapeutics-inc-abeo-releases-earnings-results-misses-expectations-by-0-07-eps.html.

A number of analysts have recently weighed in on the stock. Maxim Group set a $14.00 target price on shares of Abeona Therapeutics and gave the stock a “buy” rating in a report on Saturday, May 13th. Cantor Fitzgerald restated a “buy” rating and issued a $21.00 price objective on shares of Abeona Therapeutics in a report on Tuesday, June 6th. HC Wainwright set a $20.00 price objective on shares of Abeona Therapeutics and gave the stock a “buy” rating in a report on Wednesday, July 19th. BidaskClub lowered shares of Abeona Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Thursday, July 27th. Finally, Zacks Investment Research upgraded shares of Abeona Therapeutics from a “sell” rating to a “hold” rating in a report on Friday, June 9th. One analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. The stock currently has an average rating of “Buy” and a consensus price target of $17.86.

Abeona Therapeutics Company Profile

Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel gene therapies for life-threatening rare genetic diseases. The Company’s lead programs include ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA) and EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB).

Earnings History for Abeona Therapeutics (NASDAQ:ABEO)

Receive News & Ratings for Abeona Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abeona Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.